No change
Create an alert
Stocks and Shares ISATScan Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer. The Company's lead product candidate, TSC-101, is in development for the treatment of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) who are undergoing allogeneic hematopoietic cell transplantation (HCT). The Company is also developing multiple TCR-T therapy product candidates for the treatment of solid tumors. The Company builds a collection of therapeutic TCRs that recognize cancer-specific targets and are associated with multiple human leukocyte antigen (HLA) types, to provide customized multiplex TCR-T treatments for patients with a variety of solid tumors. Its solid tumors programs include TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204.
Company Information
About this company
Key people
Stephen R. Biggar
Independent Non-Executive Chairman of the Board
Gavin Macbeath
Chief Scientific Officer
Jason A. Amello
Chief Financial Officer, Principal Financial Officer, Principal Accounting Officer, Treasurer
Chrystal U. Louis
Chief Medical Officer
Zoran Zdraveski
Chief Legal and Strategy Officer, Secretary
Katina Dorton
Independent Director
Gabriela Gruia
Independent Director
Barbara J. Klencke
Independent Director
Garry A. Nicholson
Independent Director
Click to see more
Key facts
- Shares in issue55.82m
- EPICTCRX
- ISINUS89854M1018
- LocationUnited States
- SectorHealthcare
- IndustryBiotechnology & Drugs
- Market cap$68.11m
- Employees142
- ExchangeNASDAQ
- Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.